ArticleEmerging infectious diseases2025
Severe Group A Streptococcus Infection among Children, France, 2022-2024.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Spread ofEmerging microbes & infections · 2026Article
- Epidemiological trends of invasive Streptococcus pyogenes infections in Catalonia, 2022-2024: a two-year analysis.Infection · 2026Article
- Genomic epidemiology and molecular characterization ofMicrobiology spectrum · 2026Article
- Lysosomal permeabilization by Group AInfection and immunity · 2026Article
- Clinical features and trends of severe paediatric group A streptococcal infections in Japan in the post-COVID-19 pandemic era.Epidemiology and infection · 2026Article
- Rare emm6.10Microorganisms · 2025Article
- Lysosomal permeabilization by Group AbioRxiv : the preprint server for biology · 2025Article
- Clinical characteristics of children hospitalized with cellulitis in Spain (2016-2022). A population-based analysis.Frontiers in pediatrics · 2025Article
- Epidemiology of pediatric invasive group A streptococcus infection in a Saudi tertiary care center.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group A Streptococcus infections have increased in Europe since September 2022. The French Pediatric Intensive Care and French Pediatric Infectious Diseases expert groups conducted a retrospective and prospective study of children who had severe group A Streptococcus infections during September 1, 2022-April 1, 2024, across 34 hospitals in France. A total of 402 pediatric patients (median age 4 [interquartile range 2-7.5] years; 42% girls, 58% boys) were enrolled. Cases were characterized by a low proportion of severe skin and soft tissue infections (16%), predominance of severe upper and lower respiratory tract infections (55%), and a 3.5% case-fatality rate. In multivariate analysis, hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death. Molecular analysis revealed emm1 (73.0%) and emm12 (10.8%) strains; the M1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.